You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 1
  • 5PSQ-116 Persistence of inhibitors of interleukin-23 (anti-IL-23) for the treatment of moderate-to-severe psoriasis (msPs) in the routine clinical practice conditions

Alerts

Article menu

Download PDFPDF

Section 5: Patient safety and quality assurance
5PSQ-116 Persistence of inhibitors of interleukin-23 (anti-IL-23) for the treatment of moderate-to-severe psoriasis (msPs) in the routine clinical practice conditions
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address